Posts Archive

NCT05123131: Phase 2: Isa-RVD Study in Patients With Newly Diagnosed Multiple Myeloma (Isa-RVD) Isa-RVD Study in Patients With Newly...

NCT05014646: Phase 2: Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American...

NCT04816526: Phase 2 - Descartes-08 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After...

PRISM High Risk Smoldering Multiple Myeloma NCT04775550: Phase 2: DARA RVD For High Risk SMM (PRISM) The purpose of this research study...

REST NCT04939844: Phase 2: REST - Replacing Steroids in the Transplant Ineligble (REST) Newly diagnosed multiple myeloma patients...

ClaSPd NCT04843579: Phase 2: Treatment of Selinexor in Combination With Clarithromycin, Pomalidomide and Dexamethasone for Relapsed...

NCT04802356: Phase 2: Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients NCT04802356: Phase 2:...

NCT04891809: Phase 2 - Isatuximab in Combination With Rd Compared to Rd in Elderly Patients (Aged ≥70 Years) With NDMM As optimal...

NCT04835129: Phase 2: Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma (IMPEDE)...

NCT04786028: Phase 2 - A Study of Isatuximab Added to Standard CyBorD Induction and Lenalidomide Maintenance Treatments in ND-TEMM A...

NCT04776395 Iberdomide Alone or in Combination With Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple...

SABLe NCT04717700: Phase 2: Selinexor With Alternating Bortezomib or Lenalidomide Plus Dexamethasone in TIE Newly Diagnosed MM Patients...

NCT04850846: Phase 2: Investigation of Metformin for the Prevention of Progression of Precursor Multiple Myeloma Investigation of...

NCT04892446: Phase 2: Study of Magrolimab Combinations in Participants With Relapsed/Refractory Multiple Myeloma NCT04892446: Phase 2:...

NCT04814615: Phase 2: A Diagnostic Study of CD38-Targeted ImmunoPET of Myeloma NCT04814615: Phase 2: A Diagnostic Study of CD38-Targeted...

Phase 2 - Study of Belantamab Mafodotin as Pre- and Post-autologous Stem Cell Transplant and Maintenance for Multiple Myeloma...

NCT04392037: Phase 2: Iberdomide Combined With Low-dose Cyclophosphamide and Dexamethasone (ICON) Iberdomide Combined With Low-dose...

NCT04497961: Phase 2: A Study of Health-Related Quality of Life in People With Multiple Myeloma Receiving Daratumumab or Lenalidomide...

NCT04508790: Phase 2: Leflunomide, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma...